The Zhitong Finance App learned that the globalization of innovative drugs is changing from a narrative that has been told for many years to figures that can be checked on profit statements. On October 27, Fosun Pharmaceutical, a core subsidiary of Fosun International (00656.HK) health sector, announced results for the first three quarters of 2026: operating income of 30.463 billion yuan, up 3.64% year on year; net profit to mother of 2,667 billion yuan, up 5.71% year on year; net profit after deducting non-return to mother was 1,706 billion yuan, up 8.42% year on year. Profits are faster than revenue, and the core driving force is “continuous growth in revenue from innovative drugs and steady improvement in operating efficiency”.
Zhitongcaijing · 2d ago
Share
Listen to the news
The Zhitong Finance App learned that the globalization of innovative drugs is changing from a narrative that has been told for many years to figures that can be checked on profit statements. On October 27, Fosun Pharmaceutical, a core subsidiary of Fosun International (00656.HK) health sector, announced results for the first three quarters of 2026: operating income of 30.463 billion yuan, up 3.64% year on year; net profit to mother of 2,667 billion yuan, up 5.71% year on year; net profit after deducting non-return to mother was 1,706 billion yuan, up 8.42% year on year. Profits are faster than revenue, and the core driving force is “continuous growth in revenue from innovative drugs and steady improvement in operating efficiency”.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending